

13. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007;25(15):1960-6
14. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 2007;25(12):1539-44
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359(17):1757-65
16. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376(9742):687-97
17. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. *Nat Rev Cancer* 2006;6(9):714-27
18. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol* 2012;30(28):3499-506
19. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. *Nat Rev Cancer* 2006;6(10):813-23
20. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. *Cancer Biol Ther* 2003;2(4 Suppl 1):S134-9
21. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. *Eur J Cancer* 2004;40(6):827-36
22. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer* 2003;3(5):330-8
- **A detailed review of fluoropyrimidines for antineoplastic chemotherapy.**
23. Emura T, Suzuki N, Yamaguchi M, et al. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. *Int J Oncol* 2004;25(3):571-8
24. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. *Nat Rev Cancer* 2012;12(12):801-17
25. Rutman RJ, Cantarow A, Paschlis KE. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. *Cancer Res* 1954;14(2):119-23
26. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. *Nature* 1957;179(4561):663-6
27. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002;20(17):3617-27
28. Pritchard DM, Watson AJ, Potten CS, et al. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. *Proc Natl Acad Sci USA* 1997;94(5):1795-9
29. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. *Cancer Res* 1987;47(8):2203-6
30. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. *Cancer Res* 1996;56(11):2602-6
31. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. *J Clin Oncol* 1989;7(4):425-32
32. Hahn RG, Moertel CG, Schutt AJ, Bruckner HW. A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. *Cancer* 1975;35(4):1031-5
33. Giller SA, Zhuk RA, Lidak M. [Analogues of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolites]. *Dokl Akad Nauk SSSR* 1967;176(2):332-5
34. Ikeda K, Yoshisue K, Matsushima E, et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. *Clin Cancer Res* 2000;6(11):4409-15
35. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. *Gann* 1978;69(6):763-72
36. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. *Cancer Chemother Pharmacol* 1988;22(4):333-8
37. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. *J Clin Oncol* 2006;24(13):2059-64
38. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. *Cancer Res* 1993;53(17):4004-9
39. Hirata K, Horikoshi N, Aiba K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. *Clin Cancer Res* 1999;5(8):2000-5
40. Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. *Cancer Chemother Pharmacol* 1997;39(3):205-11
41. Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. *Expert Opin Pharmacother* 2012;13(13):1943-59
- **A recent detailed review of S-1.**
42. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of

- cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. *J Clin Oncol* 2010;28(9):1547-53
43. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. *Biochem Pharmacol* 1998;55(7):1091-7
 44. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. *Eur J Cancer* 1998;34(8):1274-81
 45. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 2001;19(8):2282-92
 46. Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. *Lancet Oncol* 2012;13(11):1125-32
 47. Emura T, Murakami Y, Nakagawa F, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. *Int J Mol Med* 2004;13(4):545-9
 48. Fukushima M, Suzuki N, Emura T, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. *Biochem Pharmacol* 2000;59(10):1227-36
 49. Heidelberger C, Parsons DG, Remy DC. Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2'-deoxyuridine. *J Med Chem* 1964;7:1-5
 50. Heidelberger C, Boohar J, Kampschroer B. Fluorinated pyrimidines. Xxiv. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 and 5-trifluoromethyl-2'-deoxyuridine-2-C-14. *Cancer Res* 1965;25:377-81
 51. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol* 2012;13(10):993-1001
 - **This trial was relevant for the approval of TAS-102 for metastatic colorectal cancer who are refractory or intolerant to standard chemotherapy.**
 52. Utsugi T. New challenges and inspired answers for anticancer drug discovery and development. *Jpn J Clin Oncol* 2013;43(10):945-53
 53. Murakami Y, Kazuno H, Emura T, et al. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. *Int J Oncol* 2000;17(2):277-83
 54. Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. *Cancer Res* 1999;59(8):1911-16
 55. Temmink OH, Emura T, de Bruin M, et al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. *Cancer Sci* 2007;98(6):779-89
 56. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature* 1989;338(6216):557-62
 57. Horchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. *J Biol Chem* 2003;278(21):19272-9
 58. Hoff PM, Bogaard K, Lassere Y, et al. Phase I safety and pharmacokinetic study of oral TAS-102 once daily for fourteen days in patients with solid tumors. *Clin Cancer Res* 2000;6:4552s-3s
 59. Hong DS, Abbruzzese JL, Bogaard K, et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. *Cancer* 2006;107(6):1383-90
 60. Overman MJ, Varadhachary G, Kopetz S, et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. *Invest New Drugs* 2008;26(5):445-54
 61. Overman MJ, Kopetz S, Varadhachary G, et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. *Cancer Invest* 2008;26(8):794-9
 62. Doi T, Ohtsu A, Yoshino T, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. *Br J Cancer* 2012;107(3):429-34
 63. Yoshino T, Mizunuma N, Yamazaki K, et al. Results of a multicenter, randomised, double-blind, phase III study of TAS-102 vs. placebo, with best supportive care (BSC), in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies. *Annals Oncol* 2014;25(Suppl 2):iii114
 64. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. *J Clin Oncol* 1991;9(3):491-8
 65. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997;15(6):2403-13
 66. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. *Semin Oncol* 1996;23(5 Suppl 10):3-15
 67. Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. *Clin Cancer Res* 2008;14(21):6744-50
 68. Robinson BW, Im MM, Ljungman M, et al. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. *Cancer Res* 2003;63(20):6935-41
 69. Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. *Cancer Res* 1994;54(12):3218-23
 70. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. *J Natl Cancer Inst* 1996;88(17):1193-203
 71. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. *Cancer Res* 1999;59(1):107-14
 72. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 2011;29(31):4105-12

73. Purcell WT, Ettinger DS. Novel antifolate drugs. *Curr Oncol Rep* 2003;5(2):114-25
74. Rosenberg B, Vancamp L, Krigas T. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode. *Nature* 1965;205:698-9
75. Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer* 2007;7(8):573-84
76. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010;362(14):1273-81
77. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. *Nat Rev Cancer* 2013;13(10):714-26
- **A excellent review of the mechanism of resistance to chemotherapy including classical cytotoxic drugs as well as molecular targeted drugs.**
78. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in *Saccharomyces cerevisiae*. *Mol Pharmacol* 2002;62(5):1154-9
79. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. *Mutat Res* 2001;478(1-2):23-43
80. Rose WC, Schurig JE. Preclinical antitumor and toxicologic profile of carboplatin. *Cancer Treat Rev* 1985;12(Suppl A):1-19
81. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. *Cancer Treat Rev* 1985;12(Suppl A):21-33
82. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. *Cancer Chemother Pharmacol* 1982;9(3):140-7
83. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. *Mol Cancer Ther* 2002;1(3):227-35
84. Kidani Y, Inagaki K, Iigo M, et al. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. *J Med Chem* 1978;21(12):1315-18
- **The authors report the discovery of oxaliplatin in 1976 at Nagoya City University, Japan.**
85. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. *Biochem Pharmacol* 1996;52(12):1855-65
86. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. *Mol Pharmacol* 2006;70(4):1390-4
87. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. *Cancer Res* 1996;56(21):4881-6
88. Spingler B, Whittington DA, Lippard SJ. 2.4 Å crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. *Inorg Chem* 2001;40(22):5596-602
89. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. *Cancer* 1992;69(4):893-900
90. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364(19):1817-25
- **A randomized study that demonstrates superiority of FOLFIRINOX than gemcitabine as first-line chemotherapy for the treatment of patients with metastatic pancreatic cancer and good performance status.**
91. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. *J Clin Oncol* 1997;15(5):1844-52
92. Matsumura Y. The drug discovery by nanomedicine and its clinical experience. *Jpn J Clin Oncol* 2014;44(6):515-25
- **A detailed review of preclinical and clinical studies of the micelle carrier systems for cancer therapy.**
93. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. *J Controlled Release* 2012;164(2):138-44
94. Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. *Cancer Res* 2003;63(24):8977-83
95. Cabral H, Murakami M, Hojo H, et al. Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. *Proc Natl Acad Sci USA* 2013;110(28):11397-402
96. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. *Cancer Sci* 2009;100(4):572-9
97. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. *Cancer Res* 1986;46(12 Pt 1):6387-92
98. Uchino H, Matsumura Y, Negishi T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. *Br J Cancer* 2005;93(6):678-87
99. Plummer R, Wilson RH, Calvert H, et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. *Br J Cancer* 2011;104(4):593-8
- **A Phase I study that demonstrates pharmacokinetic characteristics of NC-6004 different from those of cisplatin.**
100. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. *J Natl Compr Cancer Netw* 2011;9(1):13-25

Affiliation

Hiroshi Yasui¹ MD PhD,
 Giichiro Tsurita² MD PhD &
 Kohzoh Imai^{1,3} MD PhD
¹Author for correspondence
¹The University of Tokyo, The Institute of Medical Science, Center for Antibody and Vaccine, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
 E-mail: hiroyasu@ims.u-tokyo.ac.jp
²The University of Tokyo, The Institute of Medical Science, Department of Surgery, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
³Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahiku, Yokohama, 241-8515, Japan

The Use of Bone Marrow Stromal Cells (Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells) for Alveolar Bone Tissue Engineering: Basic Science to Clinical Translation

Hideaki Kagami, DDS, PhD,¹⁻³ Hideki Agata, DDS, PhD,⁴ Minoru Inoue, DDS, PhD,^{1,2} Izumi Asahina, DDS, PhD,⁴ Arinobu Tojo, MD, PhD,¹ Naohide Yamashita, MD, PhD,² and Kohzoh Imai, MD, PhD⁵

Bone tissue engineering is a promising field of regenerative medicine in which cultured cells, scaffolds, and osteogenic inductive signals are used to regenerate bone. Human bone marrow stromal cells (BMSCs) are the most commonly used cell source for bone tissue engineering. Although it is known that cell culture and induction protocols significantly affect the *in vivo* bone forming ability of BMSCs, the responsible factors of clinical outcome are poorly understood. The results from recent studies using human BMSCs have shown that factors such as passage number and length of osteogenic induction significantly affect ectopic bone formation, although such differences hardly affected the alkaline phosphatase activity or gene expression of osteogenic markers. Application of basic fibroblast growth factor helped to maintain the *in vivo* osteogenic ability of BMSCs. Importantly, responsiveness of those factors should be tested under clinical circumstances to improve the bone tissue engineering further. In this review, clinical application of bone tissue engineering was reviewed with putative underlying mechanisms.

Introduction

ATROPHIC ALVEOLAR BONE is one of the major obstacles for dental implant therapy and there are a large number of patients without sufficient bone volume. For patients with severe bone atrophy, autologous bone grafts have been performed.¹ However, even the amount of harvesting bone is small, the procedure is accompanied by swelling and pain of the donor site.² Although bioartificial bone substitutes have been frequently used, the ability to induce bone is limited.³ Accordingly, less invasive and more efficient bone regeneration therapy is awaited, such as tissue engineering.

The first results of clinical bone tissue engineering were published in 2001.⁴ In this study, the regeneration of long bone defects was tested using hydroxyapatite blocks together with cultured autologous bone marrow stromal cells (BMSCs). This tissue engineering-based approach proved the feasibility of this concept. The results from a preliminary clinical study of alveolar bone regeneration were published

thereafter.⁵ In this review, studies on clinical alveolar bone tissue engineering are summarized. Then, the problems associated with current tissue engineering were also discussed.

Bone Tissue Engineering and Stem Cells

Cells are considered as a major component of tissue engineering. Although the role of transplanted cells during bone tissue regeneration is still controversial, it has been proved that the transplanted cells could survive, proliferate, and differentiate into osteogenic phenotype.⁶ There is accumulating evidence that the level and quality of regeneration is affected by the ability of transplanted cells.⁷ Accordingly, it is important to establish an optimal cell culture protocol to maximize the function of osteogenic cells. Surprisingly, the BMSC ability to differentiate into osteoblast-like cells is easily diminished during passage and no bone formation was observed after several passages (Fig. 1).^{7,8} Furthermore, cell seeding density and the period of induction also affect *in vivo* osteogenic ability. It has been

¹Tissue Engineering Research Group, Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.


²Department of Advanced Medical Science, Clinic for Bone Regeneration, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

³Department of Oral and Maxillofacial Surgery, Matsumoto Dental University Dental School, Shiojiri, Japan.

⁴Unit of Translational Medicine, Department of Regenerative Oral Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

⁵Center for Antibody and Vaccine, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

FIG. 1. Effect of passage number on ectopic *in vivo* osteogenic ability. Upper panels showing ectopic bone formation at the back of nude mice with tissue-engineered bone using passage 1 (a) and passage 5 (b) human bone marrow stromal cells (BMSCs). The success of ectopic bone formation quickly decrease after passage and no bone formation was observed after passage 4 (c). Note that the ability is quickly lost during passage. Modified from Agata *et al.*⁷ Color images available online at www.liebertpub.com/teb



shown that basic fibroblast growth factor (bFGF) is beneficial to maintain *in vivo* osteogenic ability of BMSCs.⁷

Clinical Studies on Alveolar Bone Tissue Engineering

The results from clinical studies on alveolar bone tissue engineering using BMSCs were first reported in 2004. In

this study, bone marrow-derived MSCs were mixed with platelet-rich plasma as a scaffold.⁸ Bone regeneration was observed in all moderate atrophy cases. Another clinical study utilized BMSCs and hydroxyapatite granules. BMSCs were induced into osteogenic cells for 1 week and transplanted. In this study, bone formation was observed in three cases, but there was no apparent bone formation from the




FIG. 2. The procedure for clinical study of alveolar bone regeneration at IMSUT Hospital, The Institute of Medical Science, The University of Tokyo. β -TCP, beta-tricalcium phosphate; PRP, platelet rich plasma. Color images available online at www.liebertpub.com/teb




FIG. 3. Individual (donor) variations of *in vivo* osteogenic ability and their changes during passage. Note that the effect of passage differed between individuals. Modified from Agata.⁹ Color images available online at www.liebertpub.com/teb

transplanted cells in cases where the atrophy was severe. Thus, the efficacy of clinical alveolar bone tissue engineering for severe atrophy cases remains controversial.

We have conducted a clinical study of bone tissue engineering for severe atrophy of alveolar bone. In this study, autologous BMSCs were transplanted together with platelet-rich plasma gel and beta-tricalcium phosphate (β -TCP) granules as scaffolds (Fig. 2). The results from a 2-year observation showed that bone regeneration was observed in all patients, although significant individual variations in cell growth, differentiation, and levels of bone regeneration were observed (Asahina *et al.*, manuscript in preparation). This type of study, focused on severe atrophy cases, may prove the usefulness of alveolar bone tissue engineering. In terms of safety, no side effects or related complications have been reported, which may imply the relatively safety nature of alveolar bone tissue engineering using BMSCs.

Toward the Establishment of Reliable Alveolar Bone Tissue Engineering Using BMSCs

Although clinical studies have confirmed the feasibility and safety of alveolar bone tissue engineering using BMSCs, one of the important clinical benchmarks is the efficacy for severe atrophy cases. The results from focused studies with selected cases will provide the evidence. Another important problem is the individual variation as shown by basic and preliminary clinical studies. Since the shape and the size of bone defect vary among individuals, it might be impossible to completely eliminate such variations. Accordingly, it should be important to minimize the variation in other factors, such as cells. In terms of BMSCs, there was no significant difference in the expression of mesenchymal stem cell markers during passage.⁷ In contrast, a large variation was observed in the *in vivo* bone forming

ability among donors and during passage (Fig. 3).^{7,8,9} We believe the usage of early passage cells as well as growth factors (bFGF) may minimize the variation, which should be tested under clinical settings.

In spite of the number of studies and the clinical efficacy of bone tissue engineering, it is not a standard treatment at present. It is necessary to show the superiority of clinical outcome compared with standard autologous bone transplantation and allogenic (or xenogenic) transplantation. Furthermore, tissue engineering requires special facility for cell culture and there is a requirement for many safety examinations, which may also increase the cost for treatment. Those technologies, which may support the widespread use of bone tissue engineering, should be investigated.

Tissue engineering is one of the most rapidly progressing fields and alveolar bone is still an attractive target for tissue engineering.¹⁰ The application of bone tissue engineering is not limited for dental implants and is successfully applied for other diseases such as nonunion fractures¹¹ and alveolar clefts.^{12,13}

Disclosure Statement

No competing financial interests exist.

References

- Jensen, S.S., and Terheyden, H. Bone augmentation procedures in localized defects in the alveolar ridge: clinical results with different bone grafts and bone-substitute materials. *Int J Oral Maxillofac Implants* **24 Suppl**, 218, 2009.
- Clavero, J., and Lundgren, S. Ramus or chin grafts for maxillary sinus inlay and local onlay augmentation: comparison of donor site morbidity and complications. *Clin Implant Dent Relat Res* **5**, 154, 2003.

3. Becker, W., Urist, M., Becker, B.E., Jackson, W., Parry, D.A., Bartold, M., Vincenzi, G., De Georges, D., and Niederwanger, M. Clinical and histologic observations of sites implanted with intraoral autologous bone grafts or allografts. 15 human case reports. *J Periodontol* **67**, 1025, 1996.
4. Quatro, R., Mastrogiacomo, M., and Cancedda, R. Repair of large bone defects with the use of autologous bone marrow stromal cells. *N Engl J Med* **344**, 385, 2001.
5. Yamada, Y., Ueda, M., Hibi, H., and Nagasaka, T. Translational research for injectable tissue-engineered bone regeneration using mesenchymal stem cells and platelet-rich plasma: from basic research to clinical case study. *Cell Transplant* **13**, 343, 2004.
6. Meijer, G.J., de Bruijn, J.D., Koole, R., and van Blitterswijk, C.A. Cell based bone tissue engineering in jaw defects. *Biomaterials* **29**, 3053, 2008.
7. Agata, H., Asahina, I., Watanabe, N., Ishii, Y., Kubo, N., Ohshima, S., Yamazaki, M., Tojo, A., and Kagami, H. Characteristic change and loss of *in vivo* osteogenic abilities of human bone marrow stromal cells during passage. *Tissue Eng Part A* **16**, 663, 2010.
8. Sugiura, F., Kitoh, H., and Ishiguro, N. Osteogenic potential of rat mesenchymal stem cells after several passages. *Biochem Biophys Res Commun* **316**, 233, 2004.
9. Agata, H. Toward establishment of truly reliable protocol for bone tissue Engineering. *Regenerative Medicine*, **8**, 439, 2009. (In Japanese).
10. Egusa, H., Sonoyama, W., Nishimura, M., Atsuta, I., and Akiyama, K. Stem cells in dentistry—Part II: clinical applications. *J Prosthodont Res* **56**, 229, 2012.
11. Shoji, T., Ii, M., Mifune, Y., Matsumoto, T., Kawamoto, A., Kwon, S.M., Kuroda, T., Kuroda, R., Kurosaka, M., and Asahara, T. Local transplantation of human multipotent adipose-derived stem cells accelerates fracture healing via enhanced osteogenesis and angiogenesis. *Lab Invest* **90**, 637, 2010.
12. Pradel, W., and Lauer, G. Tissue-engineered bone grafts for osteoplasty in patients with cleft alveolus. *Ann Anat* **194**, 545, 2012.
13. Janssen, N.G., Weijs, W.L., Koole, R., Rosenberg, A.J., and Meijer, G.J. Tissue engineering strategies for alveolar cleft reconstruction: a systematic review of the literature. *Clin Oral Investig* **18**, 219, 2014.

Address correspondence to:
Hideaki Kagami, DDS, PhD
Tissue Engineering Research Group
Division of Molecular Therapy
The Advanced Clinical Research Center
The Institute of Medical Science
The University of Tokyo
4-6-1 Shirokanedai
Minato-ku
Tokyo 108-8639
Japan

E-mail: kagami@ims.u-tokyo.ac.jp

Received: September 15, 2013

Accepted: January 30, 2014

Online Publication Date: March 5, 2014

Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer

Hisayoshi Igarashi, MD, PhD¹, Hiroyoshi Kurihara, MD¹, Kei Mitsuhashi, MD¹, Miki Ito, MD¹, Hiroyuki Okuda, MD, PhD², Shinichi Kanno, MD¹, Takafumi Naito, MD¹, Shinji Yoshii, MD^{3,4}, Hiroaki Takahashi, MD, PhD³, Takaya Kusumi, MD⁵, Tadashi Hasegawa, MD, PhD⁶, Yasutaka Sukawa, MD, PhD^{1,7}, Yasushi Adachi, MD, PhD¹, Kenji Okita, MD, PhD⁸, Koichi Hirata, MD, PhD⁸, Yu Imamura, MD, PhD⁹, Yoshifumi Baba, MD, PhD⁹, Kohzoh Imai, MD, PhD¹⁰, Hiromu Suzuki, MD, PhD¹¹, Hiroyuki Yamamoto, MD, PhD¹², Katsuhiko Noshō, MD, PhD¹, and Yasuhisa Shinomura, MD, PhD¹

¹Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan; ²Department of Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan; ³Department of Gastroenterology, Keiyukai Sapporo Hospital, Sapporo, Japan; ⁴Department of Gastroenterology, NTT East Sapporo Hospital, Sapporo, Japan; ⁵Department of Surgery, Keiyukai Sapporo Hospital, Sapporo, Japan; ⁶Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan; ⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; ⁸Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan; ⁹Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan; ¹⁰Division of Cancer Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ¹¹Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan; ¹²Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

ABSTRACT

Background. Gene mutations in the pathway downstream of epidermal growth factor receptor (EGFR) are considered to induce resistance to anti-EGFR therapy in colorectal cancer (CRC). We recently reported that microRNA-31 (miR-31)-5p may regulate *BRAF* activation and play a role in the signaling pathway downstream of EGFR in CRC.

Therefore, we hypothesized that miR-31-5p can be a useful biomarker for anti-EGFR therapy in CRC.

Methods. We evaluated miR-31-5p expression and gene mutations [*KRAS* (codon 61 or 146), *NRAS* (codon 12, 13, or 61), and *BRAF* (*V600E*)] in the EGFR downstream pathway in 102 CRC patients harboring *KRAS* (codon 12 or 13) wild-type who were treated with anti-EGFR therapeutics. Progression-free survival (PFS) and overall survival (OS) were evaluated.

Results. *KRAS* (codon 61 or 146), *NRAS*, and *BRAF* mutations were detected in 6.9, 6.9, and 5.9 % patients, respectively. Compared with CRCs with at least one mutation ($n = 20$), significantly better PFS ($P = 0.0003$) but insignificantly better OS were observed in CRCs harboring all wild-type genes (*KRAS*, *NRAS*, and *BRAF*). High miR-31-5p expression was identified in 11 % ($n = 11$) patients and was significantly associated with shorter PFS ($P = 0.003$). In CRCs carrying all wild-type genes, high miR-31-5p was associated with shorter PFS ($P = 0.027$).

Conclusions. High miR-31-5p expression was associated with shorter PFS in patients with CRC treated with anti-EGFR therapeutics. Moreover, in CRCs carrying all wild-type genes, high miR-31-5p was associated with shorter

Hisayoshi Igarashi, Hiroyoshi Kurihara, Kei Mitsuhashi, and Miki Ito have contributed equally to this work.

Hiroyuki Yamamoto, Katsuhiko Noshō, and Yasuhisa Shinomura have contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1245/s10434-014-4264-7) contains supplementary material, which is available to authorized users.

© Society of Surgical Oncology 2014

First Received: 30 June 2014

K. Noshō, MD, PhD
e-mail: noshō@sapmed.ac.jp

Published online: 04 December 2014

PFS, suggesting that it may be a useful and additional prognostic biomarker for anti-EGFR therapy.

In the era of targeted therapies, monoclonal antibodies against the epidermal growth factor receptor (EGFR) have expanded the spectrum of therapeutic options and have improved the clinical outcome of patients with metastatic colorectal cancer (CRC).^{1–20} Deregulation of the signaling pathways downstream of EGFR, including the RAS/RAF/MEK/ERK pathway, is believed to induce resistance to anti-EGFR therapy.

Mutations in *KRAS* codon 12 or 13 are widely recognized as a major cause of deregulation of the RAS/RAF/MEK/ERK pathway and are negative predictors for EGFR-targeted therapies in metastatic CRC.^{4–6,20–22} The *KRAS* codon 12 or 13 mutations are found in approximately 30–40 % of metastatic CRCs; despite the prediction, more than half of the patients without a mutation in *KRAS* codon 12 or 13 do not benefit from anti-EGFR therapy.^{2–6,23}

With respect to resistance to anti-EGFR therapeutics, a mutation in *KRAS* codon 61 or 146 (which is rare but activates the RAS signaling pathway as well as mutation in codon 12 or 13) is actively studied as a possible additional predictive biomarker for anti-EGFR therapy.^{7,20} Moreover, several studies have demonstrated that mutations in gene such as *NRAS* and *BRAF* may account for the resistance, because these genes are downstream effectors of the EGFR signaling pathway, similar to the *KRAS* gene.^{8–20} Therefore, there is a need to identify additional biomarkers for more accurate selection of patients for anti-EGFR therapy.

MicroRNAs (miRNA) constitute a class of small non-coding RNA molecules (21–25 nucleotides) that function as posttranscriptional gene regulators. miRNAs can function as oncogenes or tumor suppressors. Therefore, they have been increasingly recognized as useful biomarkers of various human cancers.^{24–44} In CRC, several miRNAs are known to be deregulated and to target genes in the downstream part of the EGFR pathway, for example, miR-143 and miR-145 for *KRAS* and *BRAF*, respectively.^{27,28}

Recently, we reported that high microRNA-31 (miR-31)-5p expression was strongly associated with *BRAF* mutation and poor prognosis in a large statistical sample of CRCs.⁴⁵ In addition, we found downregulation of *BRAF* target proteins after transfection of a miR-31-5p inhibitor into the cells. These findings suggest that miR-31-5p may regulate activation of the *BRAF* gene in CRC and may play an important role in the signaling pathway downstream of EGFR.

Therefore, we hypothesized that miR-31-5p can be a useful biomarker for anti-EGFR therapy in patients with CRC. To test this hypothesis, we assessed the association of miR-31-5p expression or gene mutations [*KRAS* (codon 61 and 146), *NRAS* (codon 12, 13, and 61), and *BRAF*

(V600E)] with clinical outcomes in patients with metastatic CRC treated with anti-EGFR therapy.

MATERIALS AND METHODS

Patients and Tissue Specimens

We collected formalin-fixed, paraffin-embedded (FFPE) tissues of 102 primary tumors of CRCs of patients who underwent surgical treatment and chemotherapy with anti-EGFR antibodies at Sapporo Medical University Hospital or Keiyukai Sapporo Hospital between 1997 and 2013. All patients underwent surgical resection of primary tumor of CRC before receiving anti-EGFR therapy. None of the patients received neoadjuvant chemotherapy or radiation therapy. To clarify the association between microRNA-31-5p expression and survival in patients with metastatic CRC, we limited the patients who received 5-FU-based adjuvant chemotherapy before receiving anti-EGFR therapy. Moreover, patients with metastatic CRC who were treated with other targeted therapies [i.e., antivascular endothelial growth factor (VEGF) therapy] or radiation therapy before or after the surgical resection were excluded. The primary cancer tissues of all patients were confirmed to be both histologically EGFR-positive and without mutations in *KRAS* codons 12 and 13.

Patients' response to anti-EGFR therapy was evaluated every 8 weeks during the treatment. The therapeutic response was assessed using the response evaluation criteria in solid tumors (RECIST).⁴⁶ Progression-free survival (PFS) was defined as the time from the beginning of anti-EGFR therapy to progression or death by any cause. Patients who did not meet these criteria were censored at the date of last administration. Overall survival (OS) was defined as the time from the diagnosis of CRC to death by any cause or last follow-up. The patients were followed until death or December 2013, whichever came first. Informed consent was obtained from all patients before specimen collection. This study was approved by the institutional review boards of the participating institutions.

DNA or RNA Extraction and Molecular Analysis

DNA or RNA was extracted from FFPE tissues or colon cancer cell lines. miR-31-5p or -3p expression were analyzed by quantitative reverse transcription-PCR. For gene mutation analysis of *KRAS* (codons 61 and 146), *NRAS* (codons 12, 13, and 61), and *BRAF* (V600E), PCR and targeted pyrosequencing were performed. The details of these methods are provided in Supplementary Methods.

Statistical Analysis

JMP (version 10) software was used for statistical analysis (SAS Institute, Cary, NC, USA). All *P* values were two-sided. Univariate analysis was performed to assess clinicopathological and molecular characteristics according to the miRNA expression level; the Chi-square test or Fisher's exact test was used for categorical data, whereas analysis of variance was used to compare the mean patient age. To account for multiple hypothesis testing in associations between miRNA expression and the other ten covariates, the *P* value for significance was adjusted using the Bonferroni correction to $P = 0.005$ ($=0.05/10$).

In survival analysis, the Kaplan–Meier method and log-rank test were used to assess survival time distribution. Cox proportional hazards regression models were used to compute mortality hazard ratio (HR) according to the molecular status.

RESULTS*MicroRNA-31 Expression in CRCs*

The study included 102 patients with metastatic CRC who were treated with anti-EGFR therapy. All patients were tested for miR-31-5p or -3p expression. Eleven patients were in miR-31-5p high-expression group and 91 were in miR-31-5p low-expression group. By contrast, 25 patients were in miR-31-3p high-expression group and 77 were in miR-31-3p low-expression group (details provided in Supplementary Methods). The relative expression levels of both miRNAs were significantly correlated ($r = 0.82$; $P < 0.0001$, Supplementary Fig. 1).

Clinicopathological and Molecular Features of Patients with CRC

Table 1 shows the clinicopathological and molecular features according to miR-31-5p expression level. There was no significant difference between the miR-31-5p high-expression group and low-expression group in all clinicopathological and molecular features. Of the 102 patients with CRC treated with anti-EGFR therapy, 44 (43 %) received cetuximab and 58 (57 %) received panitumumab. *KRAS* mutations (codon 61 or 146), *NRAS* mutations (codon 12, 13, or 61), and *BRAF* mutations (*V600E*) were detected in 7 (6.9 %) patients, 7 (6.9 %) patients, and 6 (5.9 %) patients, respectively. No patient had simultaneous mutations in these three genes. Eighty-two (80 %) patients had all wild-type *KRAS*, *NRAS*, and *BRAF*.

Mutational Status and Efficacy of Anti-EGFR Therapy

During the follow-up of the 102 patients with CRC treated with anti-EGFR therapy who were eligible for survival analysis, 61 patients died (all deaths were confirmed to be attributable to CRC). The median follow-up periods for PFS and OS were 6.0 and 48 months, respectively.

In Kaplan–Meier analysis, a significant difference in PFS ($P = 0.004$) was observed between the mutated *RAS* (at least one mutation in *KRAS* or *NRAS*) group ($n = 14$) and the *RAS* wild-type group ($n = 88$; Fig. 1a). There was no significant difference in OS ($P = 0.53$) between them (Supplementary Fig. 2a). With regard to *BRAF*, no significant difference in PFS ($P = 0.055$; Fig. 1b) and significant difference in OS ($P = 0.029$; Supplementary Fig. 2b) were observed between the patients with CRC with mutation ($n = 6$) and those without mutation ($n = 96$).

In addition, compared with CRCs with at least one mutation in *KRAS*, *NRAS*, or *BRAF* ($n = 20$), significantly better PFS ($P = 0.0003$) was observed in CRCs possessing all wild-type copies of *KRAS*, *NRAS*, and *BRAF* ($n = 82$; Fig. 1c), whereas no significant difference was detected in OS ($P = 0.13$; Supplementary Fig. 2c) between them. In univariate Cox regression analysis, similar results were observed with PFS [HR 3.37; 95 % confidence interval (CI) 1.61–6.67; $P = 0.0018$; Table 2].

MicroRNA-31 Expression and Efficacy of Anti-EGFR Therapy

Median PFS and OS in the miR-31-5p high-expression group were 2.8 and 32 months, respectively; those in the miR-31-5p low-expression group were 6.1 and 51 months, respectively. In Kaplan–Meier analysis, a high miR-31-5p expression level was significantly associated with shorter PFS ($P = 0.003$; Fig. 2a). On the other hand, there was no significant difference in OS ($P = 0.86$) between them (Supplementary Fig. 3). In univariate Cox regression analysis, similar results were observed with PFS (HR 2.88; 95 % CI 1.30–5.73; $P = 0.012$; Table 2).

We also analyzed the association of miR-31-5p expression with the efficacy of anti-EGFR therapy in patients with CRC with no mutations in *KRAS*, *NRAS*, or *BRAF*. In the *RAS* wild-type group ($n = 88$), significantly shorter PFS ($P = 0.035$; Fig. 2b) was observed in the high-expression group compared with low-expression group in Kaplan–Meier analysis. Similarly, significant shorter PFS ($P = 0.0014$; Fig. 2c) was observed in the high-expression groups than low-expression group in patients with *BRAF* wild-type CRC ($n = 96$). Furthermore, a significant difference was detected in PFS ($P = 0.027$; Fig. 2d) between

TABLE 1 Clinicopathological and molecular features of 102 CRC patients who received anti-EGFR therapy

Clinicopathological or molecular feature	Total	MicroRNA-31-5p expression		<i>P</i>
		Low-expression	High-expression	
All cases	102	91	11	
Gender				
Male	72 (71 %)	62 (68 %)	10 (91 %)	0.37
Female	30 (29 %)	29 (32 %)	1 (9.1 %)	
Age (mean ± SD)	60.4 ± 11.8	60.2 ± 11.7	60.6 ± 12.1	0.77
Tumor location				
Rectum	36 (35 %)	32 (35 %)	4 (36 %)	0.83
Distal colon (splenic flexure to sigmoid colon)	42 (41 %)	37 (41 %)	5 (45 %)	
Proximal colon (cecum to transverse colon)	24 (24 %)	22 (24 %)	2 (18 %)	
Stage at resection of primary tumor				
III	44 (43 %)	40 (44 %)	4 (36 %)	0.20
IV	58 (57 %)	51 (56 %)	7 (64 %)	
Anti-EGFR agents				
Cetuximab	44 (43 %)	40 (44 %)	4 (36 %)	0.63
Panitumumab	58 (57 %)	51 (56 %)	7 (64 %)	
Line of anti-EGFR therapy				
First line	13 (13 %)	12 (13 %)	1 (9.1 %)	0.92
Second line	17 (16 %)	15 (16 %)	2 (18 %)	
Third line and beyond	72 (71 %)	64 (70 %)	8 (73 %)	
<i>KRAS</i> mutation				
Wild-type	95 (93 %)	86 (95 %)	9 (82 %)	0.11
Codon 61 mutated	3 (2.9 %)	2 (2.2 %)	1 (9.1 %)	
Codon 146 mutated	4 (3.9 %)	3 (3.3 %)	1 (9.1 %)	
<i>NRAS</i> mutation				
Wild-type	95 (93 %)	85 (93 %)	10 (91 %)	0.77
Codon 12 mutated	3 (2.9 %)	3 (3.3 %)	0 (0 %)	
Codon 13 mutated	2 (2.0 %)	2 (2.2 %)	0 (0 %)	
Codon 61 mutated	2 (2.0 %)	1 (1.1 %)	1 (9.1 %)	
<i>BRAF</i> mutation (<i>V600E</i>)				
Wild-type	96 (94 %)	87 (96 %)	9 (82 %)	0.12
Mutated	6 (5.9 %)	4 (4.4 %)	2 (18 %)	
<i>KRAS</i> (codon 61 or 146) or <i>NRAS</i> or <i>BRAF</i> mutation				
All wild-type	82 (80 %)	76 (84 %)	6 (55 %)	0.037
At least one mutation	20 (20 %)	15 (16 %)	5 (45 %)	

Percentage (%) indicates the proportion of cases with a specific clinicopathological or molecular feature within a given dichotomous category of microRNA-31-5p expression by qRT-PCR. *P* values were calculated by analysis of variance for age and by a Chi-square test or Fisher's exact test for all other variables. To account for multiple hypothesis testing in associations between microRNA-31-5p expression and other 10 covariates, the *P* value for significance was adjusted by Bonferroni correction to $P = 0.005 (=0.05/10)$

CRC colorectal cancer, *EGFR* epidermal growth factor receptor, *SD* standard deviation

the high- and low-expression groups in patients with CRC with all wild-type copies of *KRAS*, *NRAS*, and *BRAF* ($n = 82$).

By contrast, there was no significant difference in PFS ($P = 0.13$) and OS ($P = 0.49$) between the miR-31-3p high- and low-expression groups (Supplementary Fig. 4).

MicroRNA-31 Expression in Colon Cancer Cell Lines


Supplementary Fig. 5 shows relative miR-31-5p or -3p expression levels of eight cell lines. Relative expression levels of miR-31-5p were more than ten times compared with those of miR-31-3p.

TABLE 2 Cox regression analysis of CRC patients treated with anti-EGFR therapy according to gene mutational status or microRNA-31-5p expression

	Progression-free survival			
	Median (months)	Hazard ratio	95 % confidence interval	<i>P</i>
<i>KRAS</i> (codon 61 or 146) (mutation vs. wild-type)	2.5 versus 6.1	3.16	0.75–9.15	0.11
<i>NRAS</i> (codon 12, 13, or 61) (mutation vs. wild-type)	2.6 versus 6.1	2.61	0.89–6.16	0.077
<i>BRAF</i> (<i>V600E</i>) (mutation vs. wild-type)	2.0 versus 6.1	2.65	0.79–6.71	0.11
<i>KRAS</i> (codon 61 or 146) or <i>NRAS</i> or <i>BRAF</i> (at least one mutation vs. all wild-type)	2.1 versus 6.4	3.37	1.61–6.67	0.0018
MicroRNA-31-5p expression (high expression vs. low expression)	2.8 versus 6.1	2.88	1.30–5.73	0.012

CRC colorectal cancer, EGFR epidermal growth factor receptor

FIG. 1 Kaplan–Meier survival curves of patients treated with anti-EGFR therapy according to the mutational status in *KRAS*, *NRAS*, and *BRAF* genes. **a** Progression-free survival (PFS) of patients with at least one mutation in *KRAS* (codon 61 or 146) or *NRAS* (codon 12, 13, or 61) versus patients with all wild-type copies of the 2 genes. **b** PFS of patients with mutation in *BRAF* versus patients with wild-type copies of *BRAF*. **c** PFS of patients with at least one mutation in *KRAS*, *NRAS*, and *BRAF* versus all wild-type copies of the three genes



DISCUSSION

In the current study on patients with CRC who underwent surgical treatment, we elucidated the association of miR-31-5p expression or gene mutations in the pathway downstream of EGFR with the efficacy of anti-EGFR therapy. High miR-31-5p expression was strongly associated with shorter PFS in patients with CRC treated with

anti-EGFR therapeutics. Moreover, in CRCs carrying all wild-type genes, high miR-31-5p expression was associated with shorter PFS. Thus, our data support the hypothesis that miR-31-5p can be a useful biomarker for anti-EGFR therapy.

It is well established that mutations in *KRAS* codon 12 or 13 predict the lack of response to anti-EGFR therapeutics.^{4–6} Recent studies have demonstrated a correlation




FIG. 2 Kaplan–Meier survival curves of patients treated with anti-EGFR therapy according to microRNA-31-5p expression. **a** Progression-free survival (PFS) of the high-expression group versus the low-expression group. **b** PFS of the high-expression group versus the low-expression group among patients with no mutations in either

KRAS or *NRAS*. **c** PFS of the high-expression group versus the low-expression group among patients with no mutations in *BRAF*. **d** PFS of the high-expression group versus the low-expression group among patients with no mutations in *KRAS*, *NRAS*, or *BRAF*

between mutation in *KRAS* codons 61 or 146 and resistance to anti-EGFR therapeutics.^{7,8,20} Moreover, as additional RAS-activating mutations, *NRAS* mutations have been reported to predict the response in patients with CRC treated with anti-EGFR therapy.^{8,20,47–49} *BRAF* also has been reported to demonstrate a correlation between mutation and resistance to treatment with anti-EGFR therapeutics.^{7,11,13,14,16,50}

In the current study, mutations in *KRAS* (codon 61 and 146), *NRAS* (codon 12, 13, and 61), and *BRAF* (*V600E*) were detected in 7, 7, and 6 patients, respectively, among 102 patients treated with anti-EGFR therapy. We observed

significantly better PFS in CRCs possessing all wild-type copies of *KRAS*, *NRAS*, and *BRAF* compared with CRCs with at least one mutation of *KRAS*, *NRAS*, and *BRAF*, although no significant differences in OS was observed between them. These findings are almost consistent with those of previous studies and support the validity of our pyrosequencing assay for examining the gene mutations in the pathway downstream of EGFR.^{8,14,16,19,48}

Several miRNAs (i.e., miR-143 or let-7) have been reported to be associated with the efficacy of anti-EGFR therapy in metastatic CRC.^{39,40} Nevertheless, mutational analysis in these studies was performed only on *KRAS*

codons 12 and 13. In the present study, we found that high miR-31-5p expression is associated with resistance to anti-EGFR therapeutics in patients with metastatic CRC. The strength of our current study is that we conducted mutational analysis for *KRAS*, *NRAS*, and *BRAF* in those patients. With regard to miR-31, a recent study reported that upregulation of miR-31-3p is associated with poor prognosis in patients with CRC who received anti-EGFR therapy.⁵¹ In the present study, no significant association was observed between miR-31-3p expression and prognosis of patients with CRC who received anti-EGFR therapy. miR-31-3p originates from the opposite arm of the same pre-miRNA of miR-31-5p. In our data, the relative expression levels of both miRNAs were strongly correlated and the relative expression level of miR-31-3p was extremely low compared with that of miR-31-5p in colon cancer cell lines or FFPE tissues. Previous studies, which reported upregulation of miR-31 in CRCs, support our data; this is because in all of those studies, the upregulated miR-31 was not miR-31-3p but miR-31-5p.^{33–38} Thus, the deregulation of miR-31-3p in patients with CRC may be represented by a secondary change in the deregulation of miR-31-5p. These results indicate that miR-31-5p is more adequate as a biomarker than miR-31-3p.

In the present study, we also compared the utility of miR-31-5p expression with the utility of gene mutations (*KRAS*, *NRAS*, and *BRAF*) for identifying patients with metastatic CRC to be treated with anti-EGFR therapeutics. In Cox regression analysis, significantly shorter PFS was observed in miR-31-5p high-expression group than in the low-expression group. With regard to gene mutational analysis, no significant differences in PFS were detected according to single gene analysis, whereas there was significant difference according to combination analysis. The HR according to combination analysis of gene mutation was higher than that according to miR-31-5p expression in PFS. These results suggest that miR-31-5p may be inferior to combination analysis but better than mutational analysis of a single gene in the pathway downstream of EGFR as prognostic biomarker for anti-EGFR therapy.

Our study has some limitations, including the cross-sectional and observational design and the relatively small sample size of prognostic analysis. In addition, all patients underwent resection of the primary lesion of CRC before chemotherapy in the present study. These limitations may have affected prognostic analysis; OS of patients with CRC in the present study was relatively longer compared with that in large clinical trials. No significant association was detected between OS and molecular status except for *BRAF*. Future large and independent studies are necessary to confirm the correlation between miR-31-5p and unfavorable prognosis in patients with metastatic CRC who received anti-EGFR therapy.

In conclusion, we found that high miR-31-5p expression was associated with survival in patients with metastatic CRC who underwent surgical treatment and chemotherapy with anti-EGFR antibodies. Moreover, high miR-31-5p expression was associated with shorter PFS in CRC patients without gene mutations in the downstream part of the EGFR pathway, suggesting that miR-31-5p may be a useful and additional prognostic biomarker for anti-EGFR therapy.

ACKNOWLEDGMENT The authors thank the pathology departments of Sapporo Medical University Hospital and Keiyukai Sapporo Hospital for providing the tissue specimens. The authors also thank Enago (www.enago.jp) for English language review. This work was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research [Grant Numbers: 23790800 (to K.N.) and 23390200 (to Y.S.)], A-STEP (Adaptable & Seamless, Technology Transfer Program through Target-driven R&D) (to K.N.), Sapporo Jikeikai Tomoiki Foundation (to K.N.), Takeda Science Foundation (to K.N.), and Daiwa Securities Health Foundation (to H.I.).

DISCLOSURE None.

REFERENCES

- Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*. 2004;351:337–45.
- Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*. 2010;28:4697–705.
- Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol*. 2010;28:4706–13.
- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med*. 2008;359:1757–65.
- Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med*. 2009;360:1408–17.
- Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol*. 2008;26:1626–34.
- Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer*. 2009;101:715–21.
- De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol*. 2010;11:753–62.
- De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. *Ann Oncol*. 2008;19:508–15.
- Blanke CD, Goldberg RM, Grothey A, et al. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time

- change in oncology clinical trials and practice. *Oncologist*. 2011;16:1061–8.
11. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol*. 2008;26:5705–12.
 12. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol*. 2009;27:2622–9.
 13. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol*. 2009;27:5924–30.
 14. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol*. 2010;28:1254–61.
 15. De Roock W, Lambrechts D, Tejpar S. K-ras mutations and cetuximab in colorectal cancer. *N Engl J Med*. 2009;360:834; author reply 5–6.
 16. Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. *PLoS One*. 2011;6:e15980.
 17. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. *Clin Colorectal Cancer*. 2012;11:143–50.
 18. Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. *Clin Cancer Res*. 2009;15:3184–8.
 19. Pentheroudakis G, Kotoula V, De Roock W, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. *BMC Cancer*. 2013;13:49.
 20. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med*. 2013;369:1023–34.
 21. Devun F, Bousquet G, Biau J, et al. Preclinical study of the DNA repair inhibitor Dba1 in combination with chemotherapy in colorectal cancer. *J Gastroenterol*. 2012;47:266–75.
 22. Wu KL, Huang EY, Jhu EW, et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. *J Gastroenterol*. 2013;48:350–9.
 23. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol*. 2011;29:2011–9.
 24. Zhang Y, Guo J, Li D, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. *Med Oncol*. 2010;27:685–9.
 25. Bartley AN, Yao H, Barkoh BA, et al. Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. *Clin Cancer Res*. 2011;17:7283–93.
 26. Balaguer F, Moreira L, Lozano JJ, et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. *Clin Cancer Res*. 2011;17:6239–49.
 27. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. *Oncogene*. 2009;28:1385–92.
 28. Pagliuca A, Valvo C, Fabrizi E, et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. *Oncogene*. 2013;32:4806–13.
 29. Arcaroli JJ, Quackenbush KS, Powell RW, et al. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. *Clin Cancer Res*. 2012;18:2704–14.
 30. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell*. 2009;137:1032–46.
 31. Creighton CJ, Fountain MD, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. *Cancer Res*. 2010;70:1906–15.
 32. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. *Genes Chromosom Cancer*. 2012;51:473–9.
 33. Wang CJ, Zhou ZG, Wang L, et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. *Dis Markers*. 2009;26:27–34.
 34. Chang KH, Miller N, Kheirleisid EA, et al. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. *Int J Colorectal Dis*. 2011;26:1415–22.
 35. Schee K, Boye K, Abrahamson TW, et al. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. *BMC Cancer*. 2012;12:505.
 36. Cekaite L, Rantala JK, Bruun J, et al. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. *Neoplasia*. 2012;14:868–79.
 37. Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. *Oncology*. 2007;72:397–402.
 38. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. *J Biol Chem*. 2010;285:35293–302.
 39. Pichler M, Winter E, Stotz M, et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. *Br J Cancer*. 2012;106:1826–32.
 40. Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. *Ann Oncol*. 2011;22:104–9.
 41. Kurokawa K, Tanahashi T, Iima T, et al. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. *J Gastroenterol*. 2012;47:883–95.
 42. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. (2011) Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. *J Gastroenterol*. 46:1391–402.
 43. Iino I, Kikuchi H, Miyazaki S, et al. Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis. *Cancer Sci*. 2013;104:624–30.
 44. Tsuchida A, Ohno S, Wu W, et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. *Cancer Sci*. 2011;102:2264–71.
 45. Noshu K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. *Carcinogenesis*. 2014;35:776–83.
 46. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228–47.
 47. Irahara N, Baba Y, Noshu K, et al. NRAS mutations are rare in colorectal cancer. *Diagn Mol Pathol*. 2010;19:157–63.
 48. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. *Genes Chromosom Cancer*. 2011;50:307–12.

49. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. *Lancet Oncol.* 2013;14:749–59.
50. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. *N Engl J Med.* 2009;361:98–9.
51. Manceau G, Imbeaud S, Thiebaut R, et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. *Clin Cancer Res.* 2014;20:3338–47.

Clinicopathological and Molecular Characteristics of Serrated Lesions in Japanese Elderly Patients

Katsuhiko Noshō^a Hisayoshi Igarashi^a Miki Ito^a Kei Mitsuhashi^a Hiroyoshi Kurihara^a
Shinichi Kanno^a Shinji Yoshii^{e,g} Masashi Mikami^a Hiroaki Takahashi^e Takaya Kusumi^f
Masao Hosokawa^f Yasutaka Sukawa^a Yasushi Adachi^a Tadashi Hasegawa^b Kenji Okita^c
Koichi Hirata^c Reo Maruyama^d Hiromu Suzuki^d Kohzoh Imai^h Hiroyuki Yamamotoⁱ
Yasuhisa Shinomura^a

Departments of ^aGastroenterology, Rheumatology and Clinical Immunology, ^bClinical Pathology, ^cSurgery, Surgical Oncology and Science and ^dMolecular Biology, Sapporo Medical University School of Medicine, Departments of ^eGastroenterology and ^fSurgery, Keiyukai Sapporo Hospital, and ^gDepartment of Gastroenterology, NTT East Sapporo Hospital, Sapporo, ^hThe Institute of Medical Science, The University of Tokyo, Tokyo, and ⁱDivision of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

Key Words

Aging · Colonoscopy · Colorectal cancer · Hyperplastic polyp

Abstract

Background: The population in Japan is aging more rapidly than in any other country. However, no studies have determined the characteristics of the large population of elderly patients with colorectal tumors. Therefore, we examined the clinicopathological and molecular features of these tumors in elderly patients. **Methods:** In total, 1,627 colorectal tumors (393 serrated lesions, 277 non-serrated adenomas and 957 colorectal cancers) were acquired from patients. Tumor specimens were analyzed for *BRAF* and *KRAS* mutations, CpG island methylator phenotype-specific promoters (*CACNA1G*, *CDKN2A*, *IGF2* and *RUNX3*), *IGFBP7*, *MGMT*, *MLH1* and *RASSF2* methylation, microsatellite instability (MSI) and microRNA-31 (miR-31). **Results:** The frequency of elderly patients (aged ≥ 75 years) with sessile serrated adenomas (SSAs) with cytological dysplasia was higher than that of those with other serrated lesions and non-serrated adenomas ($p < 0.0001$). In elderly patients, all SSAs were located in the proximal colon

(particularly the cecum to ascending colon). High miR-31 expression, *MLH1* methylation and MSI-high status were more frequently detected in SSAs from elderly patients than in those from non-elderly patients. In contrast, no significant differences were found between older age of onset and high-grade dysplasia for traditional serrated adenomas or non-serrated adenomas in any of these molecular alterations. **Conclusion:** In elderly patients, all SSAs were located in the proximal colon. Furthermore, cytological dysplasia and molecular alterations were more frequently detected in elderly patients with SSAs than in non-elderly patients. Thus, careful colonoscopic examinations of the proximal colon are necessary for elderly patients because SSAs in those patients may exhibit malignant potential.

© 2015 S. Karger AG, Basel

Introduction

Colorectal cancer (CRC) is the third most common type of cancer worldwide [1–7]. The serrated neoplasia pathway has attracted considerable attention as an alternative pathway for CRC development, and serrated le-

Table 1. Clinical and pathological features of patients with serrated lesions and non-serrated adenomas

Clinical and pathological features	Histopathology							p
	HPs	SSAs without cytological dysplasia	SSAs with cytological dysplasia	TSAs without HGD	TSAs with HGD	non-serrated adenomas without HGD	non-serrated adenomas with HGD	
All cases	142	122	10	103	16	137	140	
Male	93 (65)	72 (59)	5 (50)	61 (59)	10 (63)	89 (65)	74 (53)	
Female	49 (35)	50 (41)	5 (50)	42 (41)	6 (37)	48 (35)	66 (47)	0.40
Age, years	58.5±12.0	57.2±11.5	74.1±4.7	61.5±13.1	62.4±13.2	66.5±10.1	65.7±10.0	<0.0001
Tumor size, mm	9.3±3.6	12.0±7.3	12.3±6.4	9.6±4.5	13.3±4.5	12.6±7.4	26.9±16.4	<0.0001
Tumor location								
Rectum	15 (11)	0	0	17 (17)	5 (31%)	15 (11)	29 (21)	
Distal colon ¹	52 (37)	17 (14)	1 (10)	46 (45)	7 (44%)	45 (34)	36 (26)	
Proximal colon ²	73 (52)	105 (86)	9 (90)	39 (38)	4 (25%)	73 (55)	74 (53)	<0.0001

Data are expressed as mean ± SD, or n with percentage in parentheses. Percentages indicate the proportion of patients of each histological type who met the criteria for a specific clinical feature. p values were calculated by ANOVA for age and tumor size, and by χ^2 or Fisher's exact test for tumor location.

¹ Sigmoid colon to splenic flexure.

² Transverse colon to cecum.

sions exhibit unique clinical, pathological or molecular features [1, 8–19]. Sessile serrated adenomas (SSAs) and traditional serrated adenomas (TSAs) are premalignant lesions, although an SSA is the principal serrated precursor of CRC [18].

The CpG island methylator phenotype (CIMP) is a distinct form of epigenomic instability [2, 17, 20–23], which causes most sporadic microsatellite instability (MSI)-high CRCs by epigenetically inactivating *MLH1* [24]. Independent of MSI, CIMP-high CRCs are associated with proximal tumor location, older age of onset, female gender and *BRAF* mutation [7, 22, 23]. In particular, there are many clinical and molecular similarities between SSA and CIMP-high CRC; for example, their proximal tumor location, *BRAF* mutation status and comparable *MLH1* methylation [10, 12, 16–18, 25, 26]. Therefore, SSAs have been hypothesized to be precursor lesions that develop into CIMP-high CRCs with *BRAF* mutations in the proximal colon [1, 10, 12, 16–18, 25, 26].

The number of elderly CRC patients is expected to increase because of the aging populations in many countries. Previous studies conducted in the USA and European countries have shown that the clinical and molecular features of elderly CRC patients include being female, proximal tumor location, *BRAF* mutation, *MLH1* methylation, CIMP-high and MSI-high status [22, 27–29]. The population in Japan is aging more rapidly than in any other country. However, no studies have determined the characteristics of CRCs and premalignant lesions, including serrated lesions, in this large population of elderly

Japanese patients. Therefore, we examined the clinical, pathological and molecular features of colorectal tumors in elderly Japanese patients.

Materials and Methods

Histopathological Evaluations of Colorectal Serrated Lesion Tissue Specimens

We collected and analyzed 1,627 tissue specimens of colorectal serrated lesions (n = 393), non-serrated adenomas (tubular or tubulovillous adenomas, n = 277) and CRCs (n = 957) from patients who underwent endoscopic resection or surgical treatment at Sapporo Medical University Hospital, Keiyukai Sapporo Hospital or JR Sapporo Hospital between 2001 and 2013. The patient demographic and clinical information is presented in table 1.

Histological findings relating to all colorectal serrated lesion specimens were evaluated by pathologists who were blinded to the clinical and molecular information. Serrated lesions, including hyperplastic polyps (HPs), SSAs and TSAs, were classified on the basis of the current World Health Organization (WHO) criteria [18]. HPs were further subdivided into microvesicular HPs and goblet cell HPs, with all being found to be microvesicular.

This study was approved by the institutional review boards of the participating institutions. Informed consent was obtained from all patients prior to specimen collection.

DNA Extraction and Pyrosequencing for *KRAS* and *BRAF* Mutations and MSI Analysis

Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissues using QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, Calif., USA) [1]. Extracted genomic DNA was used for PCR and targeted pyrosequencing for *KRAS* (codons 12 and 13) and *BRAF* (*V600E*) [6]. MSI analysis was performed as previously described [1].

Sodium Bisulfite Treatment and Real-Time PCR (MethyLight) to Determine CACNA1G, CDKN2A (p16), IGFBP7, IGF2, MGMT, MLH1, RASSF2 and RUNX3 Promoter Methylation

Bisulfite modification of genomic DNA was conducted using the BisulFlash™ DNA Modification Kit (Epigentek, Brooklyn, N.Y., USA) [17]. DNA methylation was quantified for four CIMP-specific promoters [CACNA1G, CDKN2A (p16), IGF2 and RUNX3] and IGFBP7, MGMT, MLH1 and RASSF2 using Real-Time PCR (MethyLight) [17, 30, 31]. CIMP-high status was defined as the presence of 3 of 4 or more methylated promoters and CIMP-low/zero as the presence of 0–2 of 4 methylated promoters [17].

RNA Extraction and Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) for MicroRNA-31

Total RNA was extracted from FFPE tissues using the miRNeasy FFPE Kit (Qiagen) [1]. MicroRNA-31 (miR-31)-5p expression was analyzed by qRT-PCR using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., USA) and TaqMan microRNA Assays (Applied Biosystems), as previously described [1].

Statistical Analysis

JMP (version 10) software was used for all statistical analyses (SAS Institute, Cary, N.C., USA). Univariate analysis was used to determine the clinical, pathological and molecular characteristics associated with serrated lesions and non-serrated adenomas for elderly (≥ 75 years) and non-elderly (< 75 years) patients. Group results for tumor sizes were compared by ANOVA, and results for other variables were compared by χ^2 or Fisher's exact test. A p value < 0.05 was considered significant, and all p values were two-sided. In the CRC-specific survival analysis, the Kaplan-Meier method and log-rank test were used to assess the survival time distribution. The Spearman correlation coefficient was used to assess the correlations between miR-31 expression level and tumor size.

Results

Clinical and Pathological Features of Elderly Patients with Serrated Lesions and Non-Serrated Adenomas

As shown in table 1, patients with SSAs with cytological dysplasia were significantly older (mean \pm SD 74.1 ± 4.7 years) than those with HPs (58.5 ± 12.0 years), those with SSAs without cytological dysplasia (57.2 ± 11.5 years), those with TSAs without high-grade dysplasia (HGD; 61.5 ± 13.1 years), those with TSAs with HGD (62.4 ± 13.2 years), those with non-serrated adenomas without HGD (66.5 ± 10.1 years) and those with non-serrated adenomas with HGD (65.7 ± 10.0 years, all $p < 0.0001$).

Elderly patients (aged ≥ 75 years) with serrated lesions ($n = 39$) accounted for 9.6% of the 403 patients with serrated lesions. As shown in figure 1, the frequency of elderly patients with SSA with cytological dysplasia (6/10,

60%) was significantly higher than that of those with HP (10/142, 7.0%), those with SSA without cytological dysplasia (7/122, 5.7%), those with TSA without HGD (13/103, 13%) and those with TSA with HGD (3/16, 19%, all $p < 0.0001$).

Among the elderly patients, all 13 SSAs (cecum, $n = 5$; ascending colon, $n = 6$; transverse colon, $n = 2$) were located in the proximal colon. No significant difference was found in the size of SSAs between the elderly (10.7 ± 5.4 mm) and non-elderly (12.2 ± 7.3 mm, $p = 0.49$). With regard to HPs and TSAs, no significant differences were found between elderly and non-elderly patients in any of these clinical features.

In contrast, the frequency of elderly patients with non-serrated adenoma with HGD (26/140, 19%) was nearly the same as that of those with non-serrated adenoma without HGD (28/137, 20%). No significant differences were found between elderly patients with non-serrated adenomas and non-elderly patients for other clinical features (gender, tumor size or tumor location).

Molecular Features of Serrated Lesions and Non-Serrated Adenomas in Elderly Patients

Table 2 shows the molecular features of HPs, SSAs, TSAs and non-serrated adenomas. *MLH1* methylation (46%, $p = 0.027$), MSI-high status (23%, $p = 0.0042$), and high miR-31 expression (69%, $p = 0.022$) were more frequently detected in SSAs from elderly patients (aged ≥ 75 years) than in those from non-elderly patients (18, 1.7 and 36%, respectively, aged < 75 years). No significant differences were found between elderly patients with SSAs and non-elderly patients for other molecular features.

Figure 2 represents the correlations between miR-31 expression and tumor size according to age (aged ≥ 75 or < 75 years) in SSAs. No significant correlations were found between miR-31 expression and tumor size in elderly patients ($r = 0.52$, $p = 0.068$) or non-elderly patients ($r = 0.037$, $p = 0.69$). With regard to HPs, TSAs and non-serrated adenomas, no significant differences were found between elderly and non-elderly patients in any of these molecular features.

Clinicopathological and Molecular Features of Elderly Patients with CRC

Elderly CRC patients (aged ≥ 75 years, $n = 264$) accounted for 28% of the 957 patients with CRCs. The proportion of females (55%) and the frequencies of proximal colon location (43%), *BRAF* mutation (8.3%) and CIMP-high status (36%) were significantly higher for elderly CRC patients (aged ≥ 75 years) than for non-elderly pa-




Fig. 1. Frequencies of different lesions in patients classed as elderly (≥ 75 years old, ■) and non-elderly (< 75 years old, □). Based on the histopathology of resected specimens, serrated lesions were classified as HP, SSA without cytological dysplasia, SSA with cytological dysplasia, TSA without HGD, or TSA with HGD. The frequency of elderly patients with SSA with cytological dysplasia (6/10, 60%) was significantly higher than that of those with HP (10/142, 7.0%), those with SSA without cytological dysplasia (7/122, 5.7%), those with TSA without HGD (13/103, 13%) and those with TSA with HGD (3/16, 19%, all $p < 0.0001$).




Fig. 2. Correlations between miR-31 expression and tumor size in SSAs (SSAs without cytological dysplasia, ○; SSAs with cytological dysplasia, ●) according to age: non-elderly (< 75 years old, $n = 119$; **a**) and elderly (≥ 75 years old, $n = 13$; **b**).